Source: Annual Congress 2010 - Stem cells and growth factors in lung injury
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Gay-Jordi, R. Gillamat, L. I. Sanchez, V. Sirenko, D. Closa, A. Xaubet, O. Bulbena, A. Serrano-Mollar (Barcelona, Spain). Transplant of alveolar type II cells restore pulmonary surfactant in lung fibrosis. Eur Respir J 2010; 36: Suppl. 54, 209

Member's Comments

No comment yet.

Related content which might interest you: Alveolar type II cells transplantation decrease fibrocyte migration in pulmonary fibrosis Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 Transplantation of alveolar type II cells in pulmonary fibrosis: experimental studies, MSC in IPF trials Source: International Congress 2014 – Targeting lung fibrosis: from bench to bedside Year: 2014 Thyroid hormone inhibits pulmonary fibrosis through enhancement of mitochondrial function in alveolar epithelial cells Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Aging causes alveolar epithelial type II cell dysfunction in acute lung injury Source: ERS Lung Science Conference 2020 Year: 2020 Cellular origin of pro-coagulant and (anti)-fibrinolytic factors in bleomycin-injured lungs Source: Eur Respir J 2007; 29: 1105-1114 Year: 2007 Cytokine and chemokine release in response to Pseudomonas aeruginosa (PA), by bronchial epithelium of the native airway and transplanted lung of paediatric cystic fibrosis (CF) lung transplant recipients Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new basic and clinical physiology research Year: 2012 Decreased VEGF concentration in lung tissue and vascular injury during ARDS Source: Eur Respir J 2005; 25: 139-146 Year: 2005 Defective surfactant biosynthesis and ultrastructural abnormalities of alveolar type 2 cells in pulmonary fibrosis of conditional Nedd4-2mice Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Increased alveolar soluble annexin V promotes lung inflammation and fibrosis Source: Eur Respir J 2015; 46: 1417-1429 Year: 2015 Role of macrophage activation in type II alveolar cells transplantation for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 Infection and inflammation does not effect ventilation distribution in infants with cystic fibrosis (CF) Source: Annual Congress 2011 - Cystic fibrosis: detection and monitoring of early lung disease Year: 2011 Collagen I, III and IV content in airways and lung parenchyma of COPD patients Source: Annual Congress 2010 - Proteases and the matrix Year: 2010 New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung Source: International Congress 2015 – Inflammation and remodelling in lung disease Year: 2015 Lung cysts in pulmonary alveolar proteinosis. Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Increased expression of SARS-CoV-2 (Covid-19) adhesion sites on type II pneumocytes, small airway epithelium, and alveolar macrophages in smokers and patients with COPD Source: Virtual Congress 2021 – Mechanistic pathways in chronic and new lung diseases Year: 2021 Increased urotensin II in BALF and lung tissue in rat model of COPD Source: Eur Respir J 2006; 28: Suppl. 50, 216s Year: 2006 Lung function and symptom improvement in patients with pulmonary alveolar proteinosis after whole lung lavage or N-acetylcysteine treatment Source: Eur Respir J 2005; 26: Suppl. 49, 83s Year: 2005 Effects of DNase on pulmonary function and exercise capacity in cystic fibrosis (CF) Source: Eur Respir J 2001; 18: Suppl. 33, 127s Year: 2001